273 assets in Metastatic Malignant Neoplasm

Therapeutic assets addressing Metastatic Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Metastatic Malignant Neoplasm	I-Mab Biopharma US Limited	P3	BB (70)
Irinotecan Metastatic Malignant Neoplasm	Incyte Corporation	P3	BB (69)
Nivestim Metastatic Malignant Neoplasm	Mayo Clinic	P3	BB (68)
Cyclophosphamide Metastatic Malignant Neoplasm	InSilico Medicine Hong Kong Limited	P2/3	BB (67)
Pembrolizumab Metastatic Malignant Neoplasm	InSilico Medicine Hong Kong Limited	P2/3	BB (67)
Anastrozole Metastatic Malignant Neoplasm	UNICANCER	P3	BB (66)
Dexasone Metastatic Malignant Neoplasm	Genmab	P3	BB (66)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2/3	BB (66)
Ipilimumab Metastatic Malignant Neoplasm	Federation Francophone de Cancerologie Digestive	P3	BB (66)
Letrozole Metastatic Malignant Neoplasm	UNICANCER	P3	BB (66)
Adriamycin Metastatic Malignant Neoplasm	City of Hope Medical Center	P3	BB (65)
Zoledronate Metastatic Malignant Neoplasm	Kelly Fitzgerald, MD	P3	BB (65)
Cis-Diamminedichloroplatinum Ii Metastatic Malignant Neoplasm	InSilico Medicine Hong Kong Limited	P3	BB (64)
Docetaxel Metastatic Malignant Neoplasm	InSilico Medicine Hong Kong Limited	P3	BB (64)
Floxuridine Metastatic Malignant Neoplasm	Memorial Sloan Kettering Cancer Center	P3	BB (64)
Ivonescimab Metastatic Malignant Neoplasm	Revolution Medicines, Inc.	P2	BB (64)
Lenvatinib Metastatic Malignant Neoplasm	Salubris Biotherapeutics Inc	P3	BB (64)
Nepenthe Metastatic Malignant Neoplasm	Samsung Medical Center	P2	BB (64)
Nivolumab Metastatic Malignant Neoplasm	Fred Hutchinson Cancer Center	P3	BB (64)
Oxaliplatin Metastatic Malignant Neoplasm	I-Mab Biopharma US Limited	P3	BB (64)
Sargramostim Metastatic Malignant Neoplasm	Mayo Clinic	P2	BB (64)
Tislelizumab Metastatic Malignant Neoplasm	BeOne Medicines	P3	BB (64)
Abemaciclib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P3	B (63)
Capecitabine Metastatic Malignant Neoplasm	I-Mab Biopharma US Limited	P3	B (63)
Cetuximab Metastatic Malignant Neoplasm	Revolution Medicines, Inc.	P3	B (63)
Ezabenlimab Metastatic Malignant Neoplasm	Boehringer Ingelheim	P2	B (63)
Fulvestrant Metastatic Malignant Neoplasm	Taiho Oncology, Inc.	P3	B (63)
Melphalan Metastatic Malignant Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P3	B (63)
Atezolizumab Metastatic Malignant Neoplasm	Genentech, Inc.	P2/3	B (62)
Carboplatin Metastatic Malignant Neoplasm	Revolution Medicines, Inc.	P2	B (62)
Prednisone Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P3	B (62)
Pyrotinib Metastatic Malignant Neoplasm	BeOne Medicines	P2	B (62)
Teonanacatl Metastatic Malignant Neoplasm	University of Washington	P2	B (62)
Cabozantinib Metastatic Malignant Neoplasm	Rana McKay, MD	P3	B (61)
Ibandronate Metastatic Malignant Neoplasm	Kelly Fitzgerald, MD	P3	B (60)
Muamycin Metastatic Malignant Neoplasm	City of Hope Medical Center	P3	B (60)
Nogitecan Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	B (60)
Panitumumab Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	B (60)
Fludarabine Metastatic Malignant Neoplasm	Beijing Biotech	P2	B (59)
Kras Tcr-Transduced Pbl Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	B (59)
Midazolam Metastatic Malignant Neoplasm	Cogent Biosciences, Inc.	P3	B (59)
Adagrasib Metastatic Malignant Neoplasm	Mirati Therapeutics Inc.	P2	B (58)
Crizotinib Metastatic Malignant Neoplasm	M.D. Anderson Cancer Center	P2	B (58)
Neratinib Maleate Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	B (58)
Osimertinib Metastatic Malignant Neoplasm	Shanghai Chest Hospital	P2	B (58)
Memantine Metastatic Malignant Neoplasm	NRG Oncology	P3	B (57)
Trastuzumab Metastatic Malignant Neoplasm	Seoul National University Bundang Hospital	P1/2	B (57)
Abiraterone Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (55)
Alpelisib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Bet Bromodomain Inhibitor Zen-3694 Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)

Showing 1 to 50 of 273 assets

PreviousPage 1 of 6Next